Keyphrases
Follicular Lymphoma
75%
Retrospective Analysis
50%
Mantle Cell Lymphoma
50%
Bi-national
50%
Rituximab Era
29%
Second-line Treatment
25%
Clinical Practice
25%
Bendamustine
25%
Primary Central Nervous System Lymphoma (PCNSL)
25%
Confidence Interval
25%
Better Prognosis
25%
Patient Survival
25%
Female Patients
25%
Remission
25%
Re-biopsy
25%
Fluorodeoxyglucose Positron Emission Tomography/computed Tomography
25%
Computed Tomography-guided
25%
Disease Progression
22%
Histologic Transformation
20%
High-dose Cytarabine
18%
Hazard Ratio
18%
Early Progression
18%
Excess Mortality
16%
Lymphoma
16%
Relapse Detection
15%
SUVmax
15%
Frontline Treatment
12%
Anthracyclines
12%
Cumulative Incidence
12%
Cytarabine
10%
Overall Survival
10%
Follow-up Interval
10%
Disease-specific Survival
10%
Lymphoma Patients
10%
Systematic Follow-up
10%
POD24
9%
Rituximab
8%
Trajectory Basis
8%
Rare Type
8%
Patient Demographics
8%
Treatment Facilities
8%
Multicenter Cohort
6%
Treatment Efficacy
6%
Treatment Strategy
6%
Treatment Patterns
6%
Disease Outcome
6%
Prognostic Value
6%
Finland
6%
Sex Differences
6%
Male Sex
6%
Medicine and Dentistry
Follicular Lymphoma
100%
Mantle Cell Lymphoma
75%
Diseases
52%
Primary Central Nervous System Lymphoma
50%
Positron Emission Tomography-Computed Tomography
50%
Biopsy Technique
35%
Rituximab
33%
Cytarabine
29%
Overall Survival
27%
Bendamustine
25%
Lifespan
25%
Transplantation
25%
Fluorodeoxyglucose
25%
Mortality
20%
Autologous Stem Cell Transplantation
20%
Drug Megadose
18%
Hazard Ratio
18%
Health Care Cost
16%
Chemoimmunotherapy
16%
Progression Free Survival
16%
Anthracycline
12%
B-Cell Lymphoma
12%
Cumulative Incidence
12%
Diagnosis
10%
Survival Rate
8%
Personalized Medicine
8%
Targeted Therapy
8%
Patient Population
8%
Disease Exacerbation
6%
Patient-Data
6%
Disease Specific Survival
6%
Prognostic Factor
6%
Sex Difference
6%
Retrospective Study
5%
Standardized Uptake Value
5%
Pharmacology, Toxicology and Pharmaceutical Science
Mantle Cell Lymphoma
75%
Follicular Lymphoma
50%
Diseases
37%
Rituximab
33%
Cytarabine
29%
Bendamustine
25%
Primary Central Nervous System Lymphoma
25%
Remission
25%
Overall Survival
22%
Mortality
20%
Anthracycline
12%
B Cell Lymphoma
12%
Survival Rate
8%
Progression Free Survival
6%
Disease Specific Survival
6%
